Our findings are anticipated to contribute to the development of more effective and safer clinical treatment options for HER2-positive breast cancer with liver metastasis, while simultaneously providing valuable data to enhance our understanding of the heterogeneity associated with breast cancer liver metastasis. This evidence concerns the gene ERBB2 and breast cancer.